Aix Marseille University, INSERM, INRA, C2VN, Marseille, France; Department of Nutrition, Metabolic Diseases and Endocrinology, APHM, La Conception Hospital, Marseille, France.
Department of Biochemistry, Neurologic Hospital, Lyon, France.
J Clin Lipidol. 2018 Jul-Aug;12(4):883-887. doi: 10.1016/j.jacl.2018.04.011. Epub 2018 Apr 30.
We report the first case of an autoimmune hypertriglyceridemia successfully treated with rituximab, an anti-CD20-targeted monoclonal antibody. A 45-year-old man, with prior autoimmune conditions, developed severe, acquired hypertriglyceridemia resistant to traditional triglyceride lowering therapies. After the elimination of secondary or genetic causes, we detected the presence of anti-LPL-IgG by immunoblot. After 3 infusions of rituximab, we observed a marked improvement of his hypertriglyceridemia, concomitant with a reduction in plasma anti-LPL antibody titer and B-lymphocytes counts. The patient has been receiving rituximab maintenance therapy for 5 years without any serious adverse events and with excellent control of his previous, marked hypertriglyceridemia.
我们报告了首例用利妥昔单抗（一种针对 CD20 的靶向单克隆抗体）成功治疗的自身免疫性高甘油三酯血症病例。一名 45 岁的男子，有自身免疫性疾病既往史，发生了严重的、获得性的高甘油三酯血症，对传统的降低甘油三酯的治疗方法有抗性。在排除了继发性或遗传性原因后，我们通过免疫印迹法检测到存在抗 LPL-IgG。用利妥昔单抗治疗 3 次后，我们观察到他的高甘油三酯血症明显改善，同时血浆抗 LPL 抗体滴度和 B 淋巴细胞计数降低。该患者接受利妥昔单抗维持治疗 5 年，无严重不良事件，先前明显的高甘油三酯血症得到很好的控制。
